TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,766,000 | -31.2% | 4,671,859 | +18.2% | 0.05% | -24.6% |
| Q2 2023 | $60,720,000 | -25.9% | 3,953,114 | +8.5% | 0.07% | -28.9% |
| Q1 2023 | $81,969,000 | +9.6% | 3,644,687 | +2.5% | 0.10% | +10.2% |
| Q4 2022 | $74,785,000 | -8.3% | 3,556,112 | +7.4% | 0.09% | -12.0% |
| Q3 2022 | $81,585,000 | -8.2% | 3,310,256 | -9.8% | 0.10% | 0.0% |
| Q2 2022 | $88,893,000 | -4.5% | 3,668,679 | +1.5% | 0.10% | +40.8% |
| Q1 2022 | $93,104,000 | -20.4% | 3,612,901 | -4.1% | 0.07% | -26.8% |
| Q4 2021 | $116,956,000 | +22.0% | 3,767,892 | -4.7% | 0.10% | +18.3% |
| Q3 2021 | $95,833,000 | +67.9% | 3,951,841 | +1.0% | 0.08% | +74.5% |
| Q2 2021 | $57,082,000 | -16.5% | 3,912,413 | +42.9% | 0.05% | -51.5% |
| Q1 2021 | $68,357,000 | -9.3% | 2,737,553 | -1.0% | 0.10% | -11.8% |
| Q4 2020 | $75,331,000 | – | 2,763,922 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |